Tolerability of linezolid in patients with drug-resistant TB in Daru, Western Province, PNG.

IF 1.3 Q4 RESPIRATORY SYSTEM

Public Health Action Pub Date : 2024-12-01 DOI:10.5588/pha.24.0041

M Boga, T Marukutira, A Murray, G G Chan, G K Huang

{"title":"Tolerability of linezolid in patients with drug-resistant TB in Daru, Western Province, PNG.","authors":"M Boga, T Marukutira, A Murray, G G Chan, G K Huang","doi":"10.5588/pha.24.0041","DOIUrl":null,"url":null,"abstract":"Setting: Linezolid (LZD) has emerged as a critical agent and core component of regimens to treat drug-resistant TB (DR-TB); however, there are ongoing uncertainties regarding its safety and the optimal dosing approach. Since 2016, linezolid has been used in the treatment of patients diagnosed with DR-TB at Daru Provincial Hospital, PNG.Objective: To describe the patient characteristics, treatment outcomes, and tolerability of linezolid-containing regimens used to treat DR-TB in Daru, Western Province.Design: This was a retrospective analysis of programmatic data.Results: A total of 632 eligible patients were diagnosed with DR-TB during the study period. Of these, 580 (91.8%) were commenced on a LZD-containing regimen. Among patients with baseline haemoglobin results available (380/632, 60.1%), the median value was 10.1 g/dL, with a mean corpuscular volume of 70.7 fL, 78.1% of those with haemoglobin results were anaemic at baseline. Despite this, 242/580 (41.7%) patients were able to complete the full LZD course of treatment (typically 18 months) without dose reduction or interruption. Treatment success was observed in 87.9% of the cohort. Neurotoxicity was not commonly reported, but adverse events were likely under-reported.Conclusion: In this cohort, with high rates of baseline anaemia, prolonged therapy with LZD was relatively well tolerated.","PeriodicalId":46239,"journal":{"name":"Public Health Action","volume":"14 4","pages":"158-163"},"PeriodicalIF":1.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604151/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Action","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/pha.24.0041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Setting: Linezolid (LZD) has emerged as a critical agent and core component of regimens to treat drug-resistant TB (DR-TB); however, there are ongoing uncertainties regarding its safety and the optimal dosing approach. Since 2016, linezolid has been used in the treatment of patients diagnosed with DR-TB at Daru Provincial Hospital, PNG.

Objective: To describe the patient characteristics, treatment outcomes, and tolerability of linezolid-containing regimens used to treat DR-TB in Daru, Western Province.

Design: This was a retrospective analysis of programmatic data.

Results: A total of 632 eligible patients were diagnosed with DR-TB during the study period. Of these, 580 (91.8%) were commenced on a LZD-containing regimen. Among patients with baseline haemoglobin results available (380/632, 60.1%), the median value was 10.1 g/dL, with a mean corpuscular volume of 70.7 fL, 78.1% of those with haemoglobin results were anaemic at baseline. Despite this, 242/580 (41.7%) patients were able to complete the full LZD course of treatment (typically 18 months) without dose reduction or interruption. Treatment success was observed in 87.9% of the cohort. Neurotoxicity was not commonly reported, but adverse events were likely under-reported.

Conclusion: In this cohort, with high rates of baseline anaemia, prolonged therapy with LZD was relatively well tolerated.

查看原文本刊更多论文

巴布亚新几内亚西部省达鲁耐药结核病患者对利奈唑胺的耐受性

背景：利奈唑胺（LZD）已成为治疗耐药结核病（DR-TB）方案的关键药物和核心组成部分；然而，其安全性和最佳给药方法仍存在不确定性。自2016年以来，利奈唑胺在巴布亚新几内亚达鲁省医院用于治疗被诊断为耐药结核病的患者。目的：描述西部省份达鲁市用于治疗耐药结核病的含利奈唑胺方案的患者特征、治疗结果和耐受性。设计：这是对程序性数据的回顾性分析。结果：在研究期间，共有632名符合条件的患者被诊断为耐药结核病。其中580例（91.8%）开始使用含lzd的方案。在基线血红蛋白结果可用的患者中（380/632,60.1%），中位值为10.1 g/dL，平均红细胞体积为70.7 fL， 78.1%的血红蛋白结果在基线时贫血。尽管如此，580例患者中有242例（41.7%）能够在没有减量或中断的情况下完成完整的LZD疗程（通常为18个月）。治疗成功率为87.9%。神经毒性未被普遍报道，但不良事件可能被低估。结论：在该队列中，基线贫血率高，LZD延长治疗的耐受性相对较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Public Health Action RESPIRATORY SYSTEM-

自引率

0.00%

发文量

期刊介绍： Launched on 1 May 2011, Public Health Action (PHA) is an official publication of the International Union Against Tuberculosis and Lung Disease (The Union). It is an open access, online journal available world-wide to physicians, health workers, researchers, professors, students and decision-makers, including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. PHA is a peer-reviewed scholarly journal that actively encourages, communicates and reports new knowledge, dialogue and controversy in health systems and services for people in vulnerable and resource-limited communities — all topics that reflect the mission of The Union, Health solutions for the poor.